The JAK inhibitors drug class safety issue has landed in Europe, as indicated by this European Medicines Agency (EMA) February 11, 2022, news item, “EMA starts safety review of Janus kinase inhibitors for inflammatory disorders”. This Xeljanz, Rinvoq, and Olumiant safety review by the EMA follows a December 2021 JAK inhibitors drug class safety FDA … [Read more...]
Imbruvica Increases Risks Of Myocardial Infarctions, Strokes, And Cardiovascular Deaths
Serious heart-related side effects such as myocardial infarctions, strokes, and cardiovascular deaths associated with Imbruvica (ibrutinib), according to this medical journal article, “Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation”, published in early October 2019. From the Abstract for this Blood medical journal … [Read more...]